Skip to content
drillr.ai
Sign up

301230.SZ

PharmaResources (Shanghai) Co., Ltd

SZSE · M 科研服务 · CN

CNY 30.76
+9.51%
Ask drillr

  • Oct 22, 2026, 08:52 UTC

    Shanghai Hongbo Biopharmaceutical reported first-nine-month 2026 revenue of 551 million yuan, up 7.08% year over year, and net profit attributable to shareholders of 29.0507 million yuan, down 16.40%; adjusted net profit was 1.5188 million yuan, down 94.52%.

    Source:

  • Oct 22, 2026, 08:52 UTC

    Shanghai Hongbo Biopharmaceutical reported third-quarter 2026 revenue of 186 million yuan, up 15.29% year over year, and net profit attributable to shareholders of 321,300 yuan, down 96.78%; adjusted net loss was 4.9416 million yuan.

    Source:

  • Aug 27, 2026, 10:36 UTC

    Hongbo Medicine announced its first-half 2026 results: revenue of 364 million yuan, up 3.31% year-on-year; net profit attributable to shareholders of 28.7294 million yuan, up 16.02%; non-recurring net profit of 6.4603 million yuan, down 67.95%.

    Source: